Population pharmacokinetic and pharmacodynamic modeling of different formulations of ONO-5334, cathepsin K inhibitor, in Caucasian and Japanese postmenopausal females

Serum and urine bone resorption markers and pharmacokinetics of the cathepsin K inhibitor ONO-5334 after ascending single doses in post menopausal women

(2012) Shinichi Nagase et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Fundamentals of Population Pharmacokinetic Modelling

(2012) Catherine M. T. Sherwin et al.   CLINICAL PHARMACOKINETICS

Population Pharmacokinetic/Pharmacodynamic Modeling to Assist Dosing Schedule Selection for Dovitinib

(2012) Xiaofeng Wang et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Inhibition of Cathepsin K for Treatment of Osteoporosis

(2012) Steven Boonen et al.   Current Osteoporosis Reports

Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism

(2011) Yasuo Ochi et al.   BONE

Age-Related Changes in Pharmacokinetics

(2011) Shaojun Shi et al.   CURRENT DRUG METABOLISM

Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: The OCEAN study

(2011) Richard Eastell et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Pharmacodynamic Effects on Biochemical Markers of Bone Turnover and Pharmacokinetics of the Cathepsin K Inhibitor, ONO-5334, in an Ascending Multiple-Dose, Phase 1 Study

(2011) Shinichi Nagase et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Population PK–PD model for Fc-osteoprotegerin in healthy postmenopausal women

(2008) Matthew L. Zierhut et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS